Introduction
Botulinum neurotoxin type A (BoNT/A) is used as a therapeutic tool to induce chemical denervation of spastically contracted muscles, as well as its more well-known cosmetic use. BoNT/A denervates muscle by inhibiting the release of acetylcholine at the neuromuscular junction, which prevents subsequent muscular contraction (Adhihetty et al., 2007; Jackman and Kandarian, 2004) . Neurotoxin administration can cause skeletal muscle atrophy, yet the underlying cellular proteolytic mechanism(s) that induce muscle atrophy remain unclear. The action of BoNT/A is specific only to the neuron itself, as no botulinum neurotoxin receptors have been found in tissues other than neurons. Thus, there is no evidence of a myotoxic effect by the neurotoxin.
We have previously attempted to prevent BoNT/A-induced atrophy via overexpression of Heat shock protein 70 (Hsp70) (Houston et al., 2015) . Overexpression of Hsp70 has been shown to attenuate immobilization-induced atrophy via a downregulation of the ubiquitin-proteasome system (UPS) (Senf et al., 2008) . We have shown BoNT/A treated muscle to have elevated nuclear factor kappa B (NF-kB) and forkhead boxO (Foxo) transcriptional activity, both known to be activators of the UPS. Thus, we chose to overexpress Hsp70 in BoNT/A treated muscle. However, despite Hsp70 overexpression suppressing both NF-kB and Foxo transcriptional activity in BoNT/A injected muscle, the overexpression was insufficient to significantly attenuate polyubiquitination, proteasome activity, nor fiber atrophy in BoNT/A treated muscle. Thus, we subsequently sought an approach that fully inhibits the proteasome to elucidate its contribution to BoNT/A-induced atrophy.
We have previously shown that BoNT/A injection induces elevations in 20s proteasome activity, but not 26s proteasome activity (Houston et al., 2015) . The catalytic center of the 26S proteasome is the 20S proteasome, which recognizes, binds, and unfolds ubiquitinated proteins. The 20S core is a hollow cylindrical structures comprising two pairs of 14 different polypeptides arranged in four stacked rings. Three subunits on each inner ring carry catalytic residues for the proteolytic sites -chymotrypsin-like sites cleave peptide bonds predominantly after hydrophobic residues; caspaselike sites cleave after acidic residues; and trypsin-like sites cleave after basic residues (Kisselev et al., 1999) . Of the 20s proteasome proteolytic sites, we have shown chymotrypsin-like activity to be the most active in BoNT/A treated muscle (Houston et al., 2015) . Epoxomicin is commonly used to inhibit the proteasome in vivo (Meng et al., 1999) . Unlike most proteasome inhibitors, epoxomicin acts specifically and does not inhibit non-proteasomal proteases. It irreversibly and covalently binds to the six 20S proteasome catalytic subunits, with higher affinity for the b5 subunit active site (Meng et al., 1999) . Thus, we employed epoxomicin as our method of inhibiting the 20s proteasome, and chose to use the 20s chymotrypsin-like activity as our dependent variable measurement of BoNT/A-induced proteasome activity. In addition, we also measured key markers of the UPS, including protein expression of the E3 ubiquitin ligases Atrogin-1 and Muscle RING finger protein-1 (MuRF1), and polyubiquitinated protein levels, to determine the effect of proteasome inhibition on the UPS in BoNT/A treated muscle.
The current study is the first to investigate the effect of proteasome inhibition on BoNT/A-induced skeletal muscle atrophy. Based upon the elevated UPS activity, we hypothesized that a complete inhibition of the proteasome in BoNT/A treated muscle would completely prevent atrophy.
Materials and methods

Ethical approval
Male Sprague-Dawley rats (~200 g starting weight) (Charles River Laboratories, Wilmington, MA, USA) were used for all animal experiments. All animal procedures were approved by the University of Florida Institutional Animal Care and Use Committee.
Experimental design
Following a 3-day handling period, animals were assigned to one of four main groups and sacrificed after either 3 or 10 days: Control (Vehicle daily subcutaneous (SQ) injection, Gelatin Phosphate Buffer (GPB) hind limb injection; Control þ Epox (Epoxomicin daily SQ injection, GPB hind limb injection); BoNT/A (Vehicle (Vehicle daily SQ injection, BoNT/A hind limb injection); BoNT/A þ Epox (Epoxomicin daily SQ injection, BoNT/A hind limb injection). The total number per group was 6e8 solei. Due to the contralateral effect of BoNT/A, an individual animal received either control or BoNT/A injection in both their left and right leg. Animals were euthanized either 3 days or 10 days following BoNT/A injection. Solei were collected and subsequently frozen for analysis.
Proteasome inhibition
The proteasome inhibitor epoxomicin (Boston Biochem, Boston, MA) was administered to rats at a dose of 0.55 mg kg body wt À1 $day
À1
. The inhibitor was dissolved in 60% dimethyl sulfoxide. Proteasome inhibition in rats has previously been achieved via this dosage (Smuder et al., 2014) . Animals were injected SQ 1 day prior to GPB or BoNT/A hind limb injection and then every 24 h. Rats were euthanized 3 or 10 days following GPB or BoNT/A hind limb injection.
Hind limb injections
Animals were administered an intramuscular injection of 0.1 mL of 3 unit BoNT/A (Dysport, Ipsen Pharmaceuticals, Ltd), or 0.1 mL of GPB in the triceps surae compartment of both hind limbs (1U Dysport ¼ 1 ng ¼ 1 mouse LD50). Anatomical location of the hind limb injection site has previously been described (Dodd et al., 2005) . Briefly, the rat was placed in a prone position and the length of the hind limb measured. The injection site was 70% of the length of the hind limb, proximal to the distal extremity. The injection depth was 20% of the hind limb length.
Contractile properties
For evidence of toxin effect upon force production, twitch force was determined prior to hind limb injection and immediately prior to sacrifice, as previously described (Houston et al., 2015) . Hind limb force production following 3 units Dysport injection was reduced 85% compared to control after three days and remained reduced to the same extent after ten days (data not shown), in accordance with our previous study (Pickett et al., 2008 ).
Muscle preparation and analysis
Soleus muscles were removed and either rapidly frozen in liquid nitrogen and stored at À80 C for subsequent biochemical analyses, or fixed in tissue-freezing medium and frozen for fiber sectioning and subsequent histochemical analysis.
Membrane staining
Cross-sections (10 mm) were cut with a cryostat microtome (Microm HM 550; Microm International, Walldorf, Germany) from the midbelly of the soleus muscle and fixed in 4% paraformaldehyde. The muscle sections were incubated with wheat germ agglutinin Texas Red-X conjugate (Invitrogen, Carlsbad, CA, USA) for visualization of muscle fibers with fluorescence microscopy, and images were captured with an Olympus IX50 camera (Olympus, Tokyo, Japan). The selection of fibers for cross-sectional area (CSA) analysis was undertaken as follows. The whole muscle section was divided into four quadrants and an image captured at 20Â magnification at the center of each of the four quadrants. This yields~50e100 fibers per image, depending on fiber size. Subsequently, all fibers in each captured image were measured, to yield a total of at least 250 analyzed fibers per muscle. This was repeated for 6e8 muscles per group. This technique is in accordance with previous studies (Houston et al., 2015; Senf et al., 2008) .
Western blot analyses
Whole-cell lysates used for measurement of reporter activity were subsequently used for Western blot analysis. Protein concentrations were determined using a detergent-compatible assay (Bio-Rad, Hercules, CA, USA). Samples were diluted in loading buffer (Bio-Rad, Hercules, CA, USA) containing 5% b-mercaptoethanol to achieve a protein concentration of 2 mg/ml and were heat denatured. Equal amounts of protein were loaded onto 4e15% linear gradient gels and separated using SDS225 polyacrylamide gel electrophoresis. Proteins were transferred for 90 min at 100 V onto an Immobilon-FL polyvinylidene fluoride membrane (Millipore, Bedford, MA, USA), blocked in PBS containing 5% BSA for 1 h, and incubated overnight at 4 C with primary antibody diluted in blocking buffer. The following primary antibodies were used: antiubiquitin (U-5379; Sigma-Aldrich, St. Louis, MO, USA); anti-MuRF1 (MP3401, ECM Biosciences, Versailles, KY, USA); anti-Atrogin-1 (AP2041, ECM Biosciences, Versailles, KY, USA); anti-Alpha Tubulin (sc-8035, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Following a series of washes, the membranes were incubated with Alexa Fluor 680 or IRDye800 (LI-COR Biosciences, NE, USA) fluorescent-dye conjugated secondary antibodies and visualized using the Odyssey infrared imaging system (LI-COR Biosciences, NE, USA). Relative quantification of proteins was determined by measuring the fluorescence of each lane at the appropriate molecular weight, or in the case of total ubiquitinated proteins, total fluorescence in each lane. Alpha-tubulin served as loading control and revealed protein loading was equal among all lanes.
20S proteasome activity measurement
Proteins was extracted from muscle homogenates and proteasome activities were assayed similarly to that previously described (Gomes et al., 2012) . Briefly, muscles were homogenized in a passive lysis buffer (Promega, Madison, WI, USA) and supernatant collected after centrifugation at 12,000 g for 30 min. Protein concentration was obtained and sample concentrations adjusted to 0.5 mg/mL. The chymotrypsin-like activity of the proteasomes was assayed using 20 mL of sample and fluorescently tagged substrate (Suc-LLVY-AMC e Boston Biochem, Cambridge, MA, USA). The ATPindependent 20S assays were performed in the absence of ATP. Released AMC relative fluorescence units was measured using a Spectramax microplate reader (Molecular Devices Corp., Sunnyvale, CA, USA) at an excitation wavelength of 380 nm and an emission wavelength of 460 nm following 90 min incubation at 37 C. Each assay was conducted in the absence and presence of a specific proteasome inhibitor (lactacystin -Boston Biochem, Cambridge, MA, USA) to determine proteasome-specific activity. All samples were assayed in triplicate per animal.
Statistical analyses
All statistical analyses were conducted using GraphPad Software (San Diego, CA, USA). The effect of proteolytic inhibition on skeletal muscle CSA in control vs. BoNT/A treated muscle was analyzed using a 2-way ANOVA. Post-hoc follow-up tests were conducted using Bonferroni corrected degrees of freedom. All other data were analyzed using ANOVA followed by Bonferroni corrected degrees of freedom (GraphPad Software, San Diego, CA, USA). All data are expressed as means ± SE, and significance was established at p 0.05.
Results
Three-days post BoNT/A injection
BoNT/A induced an~35% reduction in rat soleus CSA compared to absolute control (Fig. 1) , in concurrence with our recent study Fig. 1 . Soleus muscle fiber CSA 3 days following initial GPB (Con) or BoNT/A hind limb injection, and daily PBS (Con; BoNT/A) or Epoxomicin (Con þ Epox; BoNT/A þ Epox) IP injection. Left: soleus fiber CSA from~250 fibers/muscle (minimum 6 muscles per group). Bars represent means ± SE. * ¼ p < 0.05 vs. Abs Con. # ¼ p < 0.05 vs. Con þ Epox. Right: representative cross sections for each group. Red lines show muscle fiber membranes stained with Texas Red conjugate. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) Fig. 2 . Soleus muscle 20S proteasome chymotrypsin-like activity, 3 days following initial GPB (Con) or BoNT/A hind limb injection, and daily PBS (Con; BoNT/A) or Epoxomicin (Con þ Epox; BoNT/A þ Epox) IP injection. Bars represent means ± SE from at least 6 muscles per group. * ¼ p < 0.05 vs. Con. (Houston et al., 2015) . BoNT/A-induced atrophy was not significantly attenuated by the daily injection of epoxomicin (Fig. 1) . BoNT/A injection induced an almost 2-fold elevation of 20s proteasome chymotrypsin-like activity (Fig. 2) . Daily injection of epoxomicin was sufficient to abolish the BoNT/A-induced elevation of chymotrypsin-like activity to that of control (Fig. 2) , confirming that 20s proteasome chymotrypsin-like activity was indeed inhibited. Protein expression of the E3 ligases Atrogin-1 (Fig. 3) and MuRF1 (Fig. 4) were unelevated in all groups 3 days following BoNT/A injection. BoNT/A injection induced a 3-fold elevation of polyubiquitinated proteins (Fig. 5) . Daily injection of epoxomicin was insufficient to abolish the BoNT/A-induced elevation in polyubiquitinated proteins (Fig. 5) .
Ten-days post BoNT/A injection
BoNT/A injected soleus muscle exhibited an~65% decrease in CSA (Fig. 6) . A significant portion (~20%) of BoNT/A-induced atrophy was attenuated by daily epoxomicin injection (Fig. 6) . Daily epoxomicin injection also caused a 20% decrease in control muscle (Fig. 6) . BoNT/A induced an~1.5 fold elevation of 20s proteasome chymotrypsin-like activity, which daily epoxomicin injection returned to that of control (Fig. 7) . In all groups, protein expression of Atrogin-1 (Fig. 8) and MuRF1 (Fig. 9) were unelevated 10 days following BoNT/A injection. BoNT/A injected soleus muscle did not exhibit elevations in polyubiquitinated protein levels compared to control however, BoNT/A þ daily epoxomicin injection significantly elevated polyubiquitination (Fig. 10) . 
Discussion
Summary of results
Contrary to our hypothesis, proteasome inhibition in BoNT/A treated muscle did not completely abolish atrophy. Three days following BoNT/A injection, despite inhibition of the proteasome by daily epoxomicin injection, there was no attenuation of BoNT/Ainduced atrophy. However, ten days following BoNT/A injection, atrophy of the soleus was attenuated~20% via proteasome inhibition. Thus, despite proteasome inhibition being achieved by daily epoxomicin injection, atrophy was only attenuated 10 days following BoNT/A administration, and not at 3 days.
Our previous study (Houston et al., 2015) revealed no BoNT/Ainduced elevation in Atrogin-1. Again, the current study found Atrogin-1 protein expression was not elevated 3 days nor 10 days post BoNT/A injection. Thus, daily epoxomicin had no effect on Atrogin-1 expression. Similarly, the current study found MuRF1 protein expression was also not significantly elevated at either 3 or 10 days following BoNT/A injection. This finding differs slightly to our previous study (Houston et al., 2015) , which revealed significant BoNT/A-induced elevations in MuRF1 3 days post BoNT/A injection, but not at 10 days. Daily epoxomicin administration had no effect on MuRF1 protein expression.
In the current study, levels of polyubiquitinated proteins were significantly elevated 3 days following BoNT/A injection in both the BoNT/A only group and in those animals injected with BoNT/A and receiving daily proteasome inhibition. Interestingly, 10 days post BoNT/A injection polyubiquitinated protein levels returned to that of control levels in those animals who received BoNT/A only but remained significantly elevated in BoNT/A injected animals receiving daily proteasome inhibition. This finding is discussed more fully later. It is also interesting that neither Atrogin-1 nor MuRF1 protein expression were elevated at either 3 or 10 days post BoNT/A injection, despite the fact that BoNT/A-induced elevation in polyubiquitination levels were observed, at least at the 3 days post BoNT/A injection.
Proteasome inhibition, but no abolishment of atrophy
Despite the fact that epoxomicin was sufficient to inhibit the proteasome, BoNT/A-induced atrophy was not abolished. This phenomenon has been seen in other models of disuse. Smuder et al. (2014) revealed that inhibition of the proteasome via epoxomicin did not prevent mechanical ventilator-induced diaphragm muscle fiber atrophy and contractile dysfunction during 12 h of mechanical ventilation. Although the models of BoNT/A induced-atrophy and mechanical ventilation-induced atrophy are different in methodology, physiology, and duration of perturbation, they do share the phenomenon that proteasome inhibition is insufficient to protect against the atrophy induced by each respective model. Furthermore, Smuder et al. (2014) found inhibition of the proteasome did not attenuate mechanical ventilation-induced elevation of MuRF1 or polyubiquitination. Indeed, polyubiquitination was higher in mechanically ventilated diaphragm following the administration of epoxomicin than without, as seen 10 days following BoNT/A þ daily epoxomicin administration. Thus, in the current study and that of Smuder et al. (2014) , it appears that the inhibition of the proteasome induces accumulation of polyubiquitinated proteins, which are presumably unable to enter the inhibited proteasome.
Proteasome inhibition and increased polyubiquitination
A surprising phenomenon was seen in control muscle that received 10 days of daily epoxomicin injection. Interestingly, epoxomicin alone induced an~20% decrease in CSA compared to control muscle, despite the fact that chymotrypsin-like activity was not different to that of absolute control. This phenomenon has not been observed in other studies using epoxomicin (Jamart et al., 2014; Smuder et al., 2014) . However, the majority of studies did not administer daily epoxomicin for such a long duration as 10 days. It may be possible that a shutdown of the proteasome for such a length of time induces a reduction in skeletal muscle cell size. Other proteolytic mechanisms therefore, may be responsible for this 20% reduction in CSA. Other studies of skeletal muscle have attenuated atrophy via the use of a proteasome inhibitor. Beehler et al. (2006) employed the use of the proteasome inhibitor Bortezomib in physically denervated soleus muscle. Bortezomib attenuated atrophy by~50%. Polyubiquitination was reduced to that of control Fig. 9 . Relative protein expression of MuRF1 in soleus muscle 10 days following initial GPB (Con) or BoNT/A hind limb injection, and daily PBS (Con; BoNT/A) or Epoxomicin (Con þ Epox; BoNT/A þ Epox) IP injection. Bars represent means ± SE from at least 6 solei per group. Above: representative Western blot of whole-cell lysates from each group. Fig. 10 . Total ubiquitinated proteins 10 days following initial GPB (Con) or BoNT/A hind limb injection, and daily PBS (Con; BoNT/A) or Epoxomicin (Con þ Epox; BoNT/ A þ Epox) IP injection. Bars represent means ± SE from at least 6 solei per group. * ¼ p < 0.05 vs. Abs Con. # ¼ p < 0.05 vs. Con þ Epox. Above: representative Western blot of whole-cell lysates for each group. The sum fluorescence of each lane was used to quantify total ubiquitinated protein of that sample. levels, rather than the 2-fold increase induced by physical denervation. Furthermore, the proteasome inhibitor MG132 has also been shown to attenuate both immobilization (Caron et al., 2011) and unweighting-induced (Jamart et al., 2011) atrophy, and alleviate prolonged moderate compression-induced muscle pathology (Siu et al., 2011) . The discrepancy between the ineffectiveness of epoxomicin in attenuating MV and BoNT/A-induced atrophy, and the ability of other proteasome inhibitors to abolish, or significantly alleviate, atrophy in other models is unclear. It may be that epoxomicin does not serve as a potent tool for greatly combating skeletal muscle atrophy.
